Avrobio Inc (AVRO)
$1.19
Market is closed - opens 7 PM, 25 Apr 2024
Insights on Avrobio Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 52.6% return, outperforming this stock by 15.9%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 336.7%
Performance
- $1.19$1.21$1.19
0.0%
Downside
Day's Volatility :1.65%
Upside
1.65%
- $0.57$1.70$1.19
52.1%
Downside
52 Weeks Volatility :66.47%
Upside
30.0%
Returns
| Period | Avrobio Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -8.33% | 2.0% | 0.0% |
6 Months | -21.94% | 11.7% | 0.0% |
1 Year | 36.72% | 5.8% | 1.3% |
3 Years | -89.75% | 14.2% | -22.1% |
Highlights
Market Capitalization | 53.9M |
Book Value | $2.12 |
Earnings Per Share (EPS) | 0.27 |
PE Ratio | 4.44 |
Wall Street Target Price | 2.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -40.62% |
Return On Equity TTM | 14.29% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -66.0M |
Diluted Eps TTM | 0.27 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.48 |
EPS Estimate Next Year | -0.33 |
EPS Estimate Current Quarter | -0.28 |
EPS Estimate Next Quarter | -0.36 |
Analyst Recommendation
Buy
90%Buy
10%Hold
0
0%Sell
Based on 10 Wall street analysts offering stock ratings for Avrobio Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
- Current
- 1M Ago
- 3M Ago
Buy
9
9
10
Hold
1
1
2
Sell
00
00
00
Analyst Forecast
What analysts predicted
Upside of 68.07%
Current $1.19
Target $2.00
Technicals Summary
Sell
Neutral
Buy
Avrobio Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Avrobio Inc | -0.82% | -21.94% | 36.72% | -89.75% | -93.93% |
 Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
 Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
 Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
 Vertex Pharmaceuticals Incorporated | -2.67% | 11.53% | 21.99% | 86.62% | 131.89% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Avrobio Inc | 4.44 | 4.44 | NA | -0.48 | 0.14 | -0.41 | NA | 2.12 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Avrobio Inc | Buy | $53.9M | -93.93% | 4.44 | 0.0% |
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 131.89% | 28.81 | 36.68% |
Institutional Holdings
BML Capital Management LLC
8.96%TANG CAPITAL MANAGEMENT LLC
7.87%Newtyn Management LLC
6.12%Vanguard Group Inc
3.59%Acadian Asset Management LLC
3.26%Aisling Capital Management LP
2.26%
Company Information
clinical stage company focused on delivering step-change cell & gene therapies targeting cancer and rare disease.
Organization | Avrobio Inc |
Employees | 13 |
CEO | Mr. Erik John Ostrowski M.B.A. |
Industry | Health Technology |
